摘要
目的探讨本院62例弥漫大B细胞淋巴瘤(DLBCL)患者的流行病学特点及治疗措施。方法选取2011年12月至2018年12月本院收治的62例DLBCL患者,收集患者年龄、性别、首发症状、结外器官受累情况、体力状况评分(ECOG)、联合放疗、淋巴瘤国际预后指数(IPI)、B症状、一线中位化疗周期、淋巴瘤的Ann Arbor分期、是否接受手术、血清乳酸脱氢酶(LDH)、骨髓侵犯、Hans病理类型等资料,并予以DLBCL患者以CHOP为基础的化疗方案,统计62例DLBCL患者的流行病学特点,比较化疗+利妥昔单抗与单纯化疗的缓解率。结果DLBCL年龄<60岁患者占比高于≥60岁,男性患者占比高于女性,首发症状以体表淋巴结、咽部症状、胃肠道症状为主,结外器官受累以韦氏环、胃肠道、骨髓、脾为主,ECOG评分0~1分患者占比高于2分,IPI指数0或1、2、3、4或5占比依次降低,淋巴瘤的AnnArbor分期Ⅱ期占比最高,Ⅰ期最低,血清LDH水平异常患者占比高于正常,Hans病理类型非生发中心来源占比高于生发中心来源;化疗+利妥昔单抗缓解率84.38%高于单纯化疗60.00%(P<0.05)。结论DLBCL好发于60岁以下中年人群,尤其是男性,首发症状以体表淋巴结、咽部症状、胃肠道症状为主,结外器官受累以韦氏环、胃肠道、骨髓、脾为主,非生发中心来源、血清LDH异常较为常见,明确诊断时疾病分期多在Ⅱ期及以上,以CHOP化疗联合利妥昔单抗治疗能提高疾病缓解率,这可为临床早期诊治DLBCL提供参考。
Objective To explore the epidemiological characteristics and therapeutic measures of 62 patients with diffuse large B-cell lymphoma (DLBCL) in our hospital. Methods From December 2011 to December 2018, 62 DLBCL patients in our hospital were selected. Age, sex, initial symptoms, extranodal organ involvement, physical condition score (ECOG), combined radiotherapy, international prognostic index of lymphoma (IPI), B symptom, first-line median chemotherapy cycle, Ann Arbor stage of lymphoma, surgery, serum lactate dehydrogenase (LDH), bone marrow invasion, Hans pathological type were collected. CHOP-based chemotherapy regimen was given to DLBCL patients. Epidemiological characteristics of 62 DLBCL patients were analyzed, and remission rates of chemotherapy + rituximab and chemotherapy alone were compared. Results The proportion of DLBCL patients less than 60 years old was higher than that of DLBCL patients equal or more than 60 years old, and the proportion of male patients was higher than that of female patients. The initial symptoms were lymph nodes, pharynx symptoms, and gastrointestinal symptoms. The main involved extranodal organs were Wechsler's ring, gastrointestinal tract, bone marrow, and spleen. The proportion of patients with ECOG score of 0-1 was higher than that of patients with ECOG score of 2, the proportion of patients with IPI index of 0 or 1, 2, 3, 4 or 5 decreased in turn. Phase II of the Ann Arbor stage of lymphoma accounted for the highest proportion, phase I for the lowest. The proportion of patients with abnormal serum LDH level was higher than that of patients with normal serum LDH level. The proportion of non-germinal center source of Hans pathological type was higher than that of germinal center source. The remission rate of chemotherapy + rituximab was 84.38%, higher than that of chemotherapy alone (60.00%)(P<0.05). Conclusions DLBCL is predominant in middle-aged people under 60 years old, especially in men. The initial symptoms are lymph node, pharynx and gastrointestinal tract symptoms. The main extranodal organs involved are Wechsler's ring, gastrointestinal tract, bone marrow, and spleen. Abnormal serum LDH and non-germinal center sources are more common. The stage of the disease is mainly over stage II. CHOP chemotherapy combined with rituximab is used to treat DLBCL, which can improve the remission rate and make a reference for early diagnosis and treatment of DLBCL.
作者
司艳辉
王洋洋
Si Yanhui;Wang Yangyang(Department of Hematology,The First People's Hospital of Zhaoqing City,Zhaoqing 526060,China;Department of Blood Transfusion,The First People's Hospital of Zhaoqing City,Zhaoqing 526060,China)
出处
《国际医药卫生导报》
2019年第18期3077-3080,共4页
International Medicine and Health Guidance News
关键词
治疗措施
弥漫大B细胞淋巴瘤
流行病学特点
Therapeutic measure
Diffuse large B-cell lymphoma
Epidemiological characteristics
